NWRN.SW Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 05:03):

Stats
Today's Volume	29 032.00
Average Volume	66 645.00
Market Cap	135.45M
EPS	CHF0 ( 2024-03-14 )
Last Dividend	CHF0 ( N/A )
Next Dividend	CHF0 ( N/A )
P/E	-8.26
ATR14	CHF0.0490 (0.67%)

Volume Correlation

Long: -0.19 (neutral)

Short: -0.82 (strong negative)

Signal:(64.957) Neutral

Newron Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Newron Pharmaceuticals Correlation - Currency/Commodity

-0.63
( weak negative )

-0.40
( neutral )

0.00
( neutral )

-0.33
( neutral )

0.20
( neutral )

-0.02
( neutral )

Newron Pharmaceuticals Financials

Annual	2023
Revenue:	CHF9.06M
Gross Profit:	CHF9.06M (100.00 %)
EPS:	CHF-0.910

FY	2023
Revenue:	CHF9.06M
Gross Profit:	CHF9.06M (100.00 %)
EPS:	CHF-0.910

FY	2022
Revenue:	CHF6.09M
Gross Profit:	CHF6.09M (100.00 %)
EPS:	CHF-0.980

FY	2021
Revenue:	CHF5.76M
Gross Profit:	CHF0.00 (0.00 %)
EPS:	CHF-0.840

Financial Reports:

No articles found.

Newron Pharmaceuticals

Newron Pharmaceuticals S.p.A., a clinical stage biopharmaceutical company, focuses on the research and development of therapies for the treatment of central and peripheral nervous system, and pain in Italy and the United States. The company offers Xadago (safinamide) for the treatment of Parkinson's disease, as well as develops Xadago for the treatment of levodopa induced dyskinesia. It also develops Evenamide for Schizophrenia and treatment resistant schizophrenia; and Ralfinamide for orphan indication in neuropathic pain. Newron Pharmaceuticals S.p.A. was founded in 1999 and is headquartered in Bresso, Italy.